Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment

Harangi, Mariann; Serés, I.; Harangi, János; Paragh, György

doi:10.1007/s10557-009-6205-4

Cited by 21 publications

(23 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Statins, apart from the capacity of lowering cholesterol levels by inhibiting the enzyme HMG-CoA reductase, provide anti-oxidative protection by increasing PON1 mass and activity. 16 Considering that 35-40% of the patients of our study were under statin therapy, we may assume that in those patients statins have protective effect on PON1 levels, a fact that was confirmed by the increase of HDL3-C and not HDL2-C levels. As known, HDL3-C subclass constitutes a large proportion of antioxidant enzymes within HDL, including PON1, whereas HDL2-C is mostly involved in removal of cholesterol in patients with end-stage renal disease.…”

Section: Discussionmentioning

confidence: 65%

“…15 On the other hand, it has been found that statin therapy can increase PON1 activity in combination with HDL-levels and cholesterol efflux capacity in dyslipidemic patients. 16,17 CONTACT The present study aimed to compare PON1 concentration in patients with renal failure (RF) and CKD patients on HD, without or with statin therapy. We also analyzed the association of PON1 with lipids, lipoproteins, apolipoproteins, as well as HDL2 and HDL3-C subclasses, which concur in different way to HDL-C protective effect.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are at high risk of atherosclerotic events; dyslipoproteinemia and the decrease of the HDL-linked enzyme paraoxonase 1 (PON1), might have a major role. This study intends to compare the association between lipid profile and serum PON1 levels in renal failure (RF) and hemodialysis (HD) patients. Serum lipids, HDL-subclasses and PON1 concentration were evaluated in 90 patients with CKD, divided into groups: RF (n ¼ 46) and HD (n ¼ 44), and in 30 normal individuals (control group). The results showed that PON1 was significantly lower in HD patients than in RF and controls (p50.001). In RF patients under statin therapy, PON1 did not differ from that of patients without statins. In HD patients without statins, PON1 was considerably low, whereas in HD with statins (30.42 ± 12.62 mg/mL) was lower than RF with statins (49.31 ± 14.94, p50.001). PON1 concentration was significantly and positively associated with HDL-C, HDL3-C and Apo A1 in all groups. Additionally, in HD patients PON1 was negatively associated with LDL-C. Multiple regression analysis revealed that LDL-C and statin treatment were independently related to PON1 concentration in HD patients (b ¼ À0.331, p ¼ 0.026 and b ¼ 0.344, p ¼ 0.020, respectively). In RF patients, HDL3-C and Apo A1 are strong determinants of PON1 levels. It is concluded that different parameters of lipid profile seem to affect serum PON1 concentration of RF and HD patients and probably contribute to the delay of atherosclerosis.ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Introductionmentioning

confidence: 99%

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Thus, parallel to this lack of difference between lipid profiles, no correlation between the lipid profile and Gensini score was observed. Several reports have investigated the effect of lipid-lowering therapy or drugs on PON1 activity and expression 49) . Although in the majority of clinical studies it has been shown that serum PON1 activity was modestly increased in patients taking lipid-lowering therapy, no consensus has been reached, probably due to population heterogeneity and assay method differences.…”

Section: Discussionmentioning

confidence: 99%

Serum PON-1 Activity but not Q192R Polymorphism is Related to the Extent of Atherosclerosis

Bayrak

Tokgözoğlu

et al. 2012

JAT

View full text Add to dashboard Cite

Aim: Paraoxonase-1 (PON1) is an antioxidant enzyme located in high density lipoprotein (HDL). PON1 was defined as a protective factor against atherosclerosis. The aim of this study was to investigate the possible relationship between serum paraoxonase (PONase), homocysteine thiolactonase (HTase) activities and PON1 Q192R polymorphism, and the extent and severity of atherosclerosis. Methods: Blood specimens were collected from 142 individuals who had no coronary artery lesions angiographically (control group) and 128 individuals who had angiographically documented coronary artery disease of several degrees (patient group). The extent and severity of arterial lesions were evaluated by the Gensini scoring system. PONase and HTase activities were measured in serum using a spectrophotometric method. PON1 Q192R polymorphism was evaluated using PCR-RFLP after DNA isolation from blood. Results: Serum PONase and HTase activities were significantly lower in the patient group than in healthy controls (135.7 56.0 U/mL vs 153.8 62.0 U/mL, p 0.05; 36.0 6.1 U/mL vs 43.0 4.04 U/mL, p 0.01; respectively). In the patient group, there was a negative correlation between PONase, HTase activities and the Gensini score (r 0.168, p 0.039; r 0.164, p 0.006, respectively). In both groups, there was no significant difference in the distribution of PON1 Q192R polymorphism. In the patient group, the distribution of Gensini scores according to genotypes was not significant. Conclusion: It has been concluded that serum PONase and HTase activities might be a more relevant marker than PON1 genotype in evaluating the extent and severity of atherosclerosis.

show abstract

“…At the same time, it must be noted that lipid lowering agents, such as statins [12,13] , fibrates [14] and ezetimibe [15] have a significant effect on HDL composition and function. Consequently, evaluating the effect of various lipid abnormalities on HDL properties in patients on lipid lowering therapy can be misleading [16] . Therefore, we investigated the structural and some functional HDL proper ties in newly diagnosed, untreated dyslipidemic patients and in healthy controls to evaluate the effect of dyslipidemia on the structural and functional properties of HDL characterized by the serum levels of HDL subfractions and MPO, PON1 paraoxonase and arylesterase activities and PON1 phenotyping.…”

Section: Introductionmentioning

confidence: 99%

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Harangi¹,

Szentpéteri²,

Nádró³

et al. 2017

Self Cite

View full text Add to dashboard Cite

Aim:The protective role of high-density lipoprotein (HDL) against atherosclerosis is well known. However, both structural and functional changes of the HDL particles may affect its protective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreased HDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Some changes in HDL subfraction distributions were also studied previously, but data on structural and functional changes in dyslipidemia are not complete. Therefore, the authors aimed to evaluate these qualitative and quantitative markers of HDL in dyslipidemic patients and healthy control subjects. Methods: Anthropometric parameters, serum levels of lipoproteins and MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patients and in 32 healthy gender-matched controls. Additionally, HDL subfractions were detected by an electrophoretic method on polyacrylamide gel (Lipoprint). Results: Significantly higher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol, triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were found in patients compared to the healthy subjects. There were no significant differences in PON1 paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratio was significantly higher in patients. There was a shift towards the smaller HDL subfractions, but only the intermediate HDL ratio was significantly lower in patients compared to controls. Conclusion:The results highlight the importance of HDL-associated pro-and antioxidant enzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm that quantification of HDL-C level alone provides limited data regarding HDL's cardioprotective effect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia. Key words:High-density lipoprotein, subfraction, paraoxonase, myeloperoxidase, dyslipidemia ABSTRACTArticle history:

show abstract

Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment

Cited by 21 publications

References 95 publications

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Serum PON-1 Activity but not Q192R Polymorphism is Related to the Extent of Atherosclerosis

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Contact Info

Product

Resources

About